Dr Reddy's Laboratories has announced that its board of directors will convene on January 21, 2026 to consider and approve the company's Q3FY26 financial results. The pharmaceutical major will release results for the quarter and nine months ended December 31, 2025, following standard corporate governance practices.

Board Meeting and Results Release

The company has formally notified stakeholders about the upcoming board meeting through a regulatory filing under Regulation 30. The results will be announced after the board meeting concludes, with distribution across multiple channels including stock exchanges, media, and the company website.

Earnings Call Schedule

Following the results announcement, Dr Reddy's Laboratories management will host an earnings call to discuss the company's financial performance. The call is scheduled for January 21, 2026 at 19:30 PM IST (9:00 AM ET).

Stakeholder Access

The company will make comprehensive information available to stakeholders through multiple formats. A press meet presentation will be accessible on the company website, while both audio recordings and transcripts of the earnings call will be made available post-event on the company website and filed with stock exchanges.

As one of India's prominent pharmaceutical companies, Dr Reddy's Laboratories' quarterly results are closely monitored by investors, analysts, and industry observers for insights into operational performance and financial health during the reporting period.

Dr. Reddy's Laboratories has disclosed receiving five separate orders from the GST Authority imposing penalties totaling ₹8.38 crores for alleged tax violations spanning FY 2018-19 to FY 2022-23. The pharmaceutical company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on January 1, 2026.

GST Authority Orders Details

The Joint Commissioner, Office of Principal Commissioner of Central Tax, Visakhapatnam issued all five orders on December 31, 2025, which were received by the company on the same date. The orders seek demand including interest and levy penalties under the APGST Act 2017, alleging that Dr. Reddy's Laboratories availed excess input tax credit during the specified period.

Financial Year-wise Penalty Breakdown

The GST orders impose varying penalty amounts across the five financial years under scrutiny:

The highest penalty of ₹3.53 crores pertains to FY 2020-21, while the lowest penalty of ₹80.41 lakhs relates to FY 2019-20.

Company's Response and Impact Assessment

Dr. Reddy's Laboratories has stated that based on its evaluation, there is no material impact on the company's financials, operations, or other activities. The company indicated it will evaluate filing the necessary appeal with the appellate authority regarding these orders.

Regulatory Compliance

The disclosure was made in compliance with SEBI regulations, with the company providing detailed information about the nature of violations, receipt dates of orders, and financial implications. Company Secretary, Compliance Officer & Head-CSR K Randhir Singh signed the regulatory filing on behalf of Dr. Reddy's Laboratories Limited.

The orders represent the GST Authority's allegation that the company claimed excess input tax credit, though the company maintains its position that there will be no material adverse impact on its business operations.